CTLA-4-directed Antibody Interactions [MoA]: Side Effects & Safety Data for 2 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
CTLA-4-directed Antibody Interactions [MoA] includes 2 drugs with a combined 38,915 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
2
Drugs in Class
38,915
Combined Reports
All CTLA-4-directed Antibody Interactions [MoA] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| IPILIMUMAB | YERVOY | 36,528 | 8,043 | 17,031 | 22.0% |
| TREMELIMUMAB | IMJUDO | 2,387 | 594 | 1,510 | 24.9% |
Common Side Effects in CTLA-4-directed Antibody Interactions [MoA] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Death | 3,826 | 3,825 |
| Malignant neoplasm progression | 3,364 | 1,592 |
| Diarrhoea | 2,693 | 336 |
| Off label use | 2,141 | 531 |
| Colitis | 2,103 | 319 |
| Pyrexia | 1,974 | 258 |
| Rash | 1,604 | 171 |
| Fatigue | 1,494 | 183 |
| Intentional product use issue | 1,334 | 563 |
| Nausea | 1,220 | 150 |